Introduction {#S1}
============

Currently, coronary heart disease (CHD) holds the leading position among all causes of mortality \[[@ref1]\]. Coronary artery bypass grafting (CABG) is considered the most effective and long-lasting method of CHD treatment due to positive postponed results \[[@ref2]\]. However, during surgical intervention, patients are subjected to additional risk, which is caused by the surgery itself as well as pathophysiological changes in homeostasis, caused by the action of anesthetics and cardiopulmonary bypass \[[@ref3]\].

Thus, according to modern studies, cardiac procedures with involvement of cardiopulmonary bypass (CPB) are able to provoke the development of systemic inflammatory response syndrome (SIRS) \[[@ref4]\]. Contact of blood components with the foreign surface of the extracorporeal contour, ischemia-reperfusion injuries, endotoxemia and surgical trauma are among the processes which can cause SIRS development during surgery \[[@ref5]\]. In turn, the development of an excessive inflammatory response triggers a cascade of apoptotic reactions in the internal organs and blood cells \[[@ref6]\]. Consequently, different post-surgical complications may develop, such as myocardial dysfunction, respiratory failure, neurological and renal dysfunction, impairment of blood clotting, disturbance of liver function and even multiple organ failure, etc. \[[@ref7]\].

Production of pro-inflammatory cytokines, in particular interleukin-6 (IL-6), is an important component in pathogenesis of CPB-associated complications \[[@ref8]\]. IL-6 is considered an important biomarker of cardiac activity condition and myocardial damage, as well as one of the inflammatory markers of coronary plaque, and in high concentrations it is detected in fatty streaks of atherosclerotic plaque \[[@ref9], [@ref10]\]. Moreover, according to data of some studies, high plasma concentration of IL-6 in patients with acute coronary syndrome is associated with the risk of serious coronary events \[[@ref11]\].

Aim {#S2}
===

The aim of our research was to assess the influence of a low-dose opioid scheme of anesthetic management on dynamics of cytokines (IL-6) in CABG with CPB.

Material and methods {#S3}
====================

Study population {#S3_1}
----------------

The study involved 60 patients with coronary heart disease, who had undergone coronary artery bypass grafting with cardiopulmonary bypass in State Institution "Heart Institute Ministry of Health of Ukraine". The mean age of patients was 60.6 ±4.1 years (from 48 to 65 years). Mean body weight -- 90.5 ±13.8 kg (from 73 to 125 kg). The number of males was 40 (66.7%), females -- 20 (33.3%). The mean EuroSCORE II value was 3.6 ±0.8%.

Exclusion criteria {#S3_2}
------------------

-- Emergency surgery.-- Redo surgery.-- Patients with the left internal mammary artery -- left anterior descending coronary artery bypass graft.-- Patients with 1 aorto-coronary anastomosis and patients with 4 or more aorto-coronary anastomoses.-- EuroSCORE II more than 5%.

Randomization {#S3_3}
-------------

According to the scheme of anesthetic management, all patients were divided into two groups. We used computer-generated lists for randomization.

Characteristics of groups {#S3_4}
-------------------------

Group I (30 patients) -- induction implied intravenous injection of propofol at the dose of 1.5--2.0 mg/kg, 40 mg with an interval of 10--15 seconds. After introduction of hypnotics, all patients received 1.5 µg/kg of fentanyl intravenously. After achieving an adequate level of anesthesia, muscle relaxation was achieved by intravenous injection of pipecuronium bromide at the dose of 0.1 mg/kg followed by intubation of the trachea. To maintain anesthesia, inhalation of sevoflurane was applied via a semi-closed contour with targeted maintenance of its concentration according to the age index of minimum alveolar concentration (MAC). Targeted concentration of sevoflurane was calculated by the formula: MAC-awake = 0.34 × MACtabl × 2. Before the onset of surgical intervention, a sub-narcotic dose of ketamine (0.5 mg/kg) was added intravenously and 1 mg/kg of lidocaine in bolus injection, with simultaneous continuous infusion of the latter at the dose of 1.5--2 mg/kg/hour and dexmedetomidine 0.7 µg/kg/hour. Infusion of lidocaine was maintained throughout the entire operation until admission of the patient to the intensive care ward. Maintenance of analgesia during surgery was performed with fentanyl injection, if necessary.

The second group (30 patients) -- standard scheme of anesthetic management (induction into anesthesia -- similar to that in patients of the first group); maintenance of anesthesia -- sevoflurane 1.5--2 MAC, standard doses of fentanyl 20--25 mg/kg during entire operation, pipecuronium bromide -- at the dose of 0.1 mg/kg.

Characteristics of these groups are presented in [Table I](#T1){ref-type="table"}.

###### 

Characteristics of patient study groups

  ----------------------------------------------------------------------------------
  Index                              Group I\     Group II\    *P*-value,\   
                                     (*n* = 30)   (*n* = 30)   α = 0.05      
  ---------------------------------- ------------ ------------ ------------- -------
  Female sex, *n* (%)                9 (30.00)    11 (26.67)   0.421         

  Age, mean ± SD \[years\]           59.8 ±4.9    60.3 ±4.2    0.851         

  Body weight, mean ± SD \[kg\]      92.1 ±22.2   88.7 ±20.1   0.505         

  Myocardial infarction\             8 (25.67)    7 (23.33)    0.205         
  in anamnesis, *n* (%)                                                      

  Diabetes type II, *n* (%)          3 (10.0)     2 (6.7)      0.381         

  PCI in anamnesis, *n* (%)          4 (13.3)     7 (23.3)     0.141         

  Arterial hypertension, *n* (%)     21 (70.0)    23 (76.7)    0.506         

  Stroke in anamnesis, *n* (%)       1 (3.3)      1 (3.3)      1.0           

  EuroSCORE II, mean ± SD %          3.5 ±0.6     3.6 ±0.9     0.193         

  Functional class NYHA, *n* (%):                                            

                                     II           13 (43.33)   11 (36.67)    0.417

                                     III          17 (56.67)   19 (63.33)    

  LVEF, mean ± SD %                  46.5 ±8.1    47.2 ±9.6    0.681         

  LVEF \< 30,0%, *n* (%)             6 (20.0)     8 (26.7)     0.461         

  Creatinine, mean ± SD \[mmol/l\]   96.5 ±11.4   89.8 ±16.3   0.09          
  ----------------------------------------------------------------------------------

Perioperative procedure {#S3_5}
-----------------------

Mechanical ventilation (MV) in examined patients was performed using an oxygen/air mixture with FiO~2~ 50% in the regimen of normal ventilation controlling gas composition of blood.

CPB was conducted using a System 1 device (Terumo, USA) with Affinity disposable membranous oxygenators (Medtronic, USA) under conditions of moderate hypothermia (+32°C).

Connection of CPB machine and perfusion during artificial electrical cardiac fibrillation was performed in non-pulsatile mode with further transition to pulsatile mode of CPB (cardiac index was maintained at the level of 2.4--2.5 l/min/m^2^). During CPB, normovolemic hemodilution was used with the level of hematocrit 25--30% and hemoglobin 80--90 g/l. Blood clotting was assessed by the activated clotting time (ACT), maintaining it within 480--600 seconds.

The endpoints analyzed in this study included low cardiac output syndrome (LCOS). LCOS includes decreases in the cardiac index (CI) to \< 2.0 l/min/m^2^ and a systolic blood pressure of \< 90 mm Hg, in conjunction with signs of tissue hypoperfusion (cold periphery, clammy skin, confusion, oliguria, elevated lactate level) in the absence of hypovolemia.

Determination of IL-6 {#S3_6}
---------------------

Determination of blood IL-6 level was performed before and after completion of CPB using the ELISA method with a set by Immunotech (a Coulter company, France).

The study was conducted in accordance with the seventh revision of the principles of the Declaration of Helsinki on Human Rights (2013). Informed consent was obtained from the patients.

Statistical analysis {#S3_7}
--------------------

The obtained results were statistically assessed using Student's *t*-test. The data are presented as the arithmetic mean (M) based on the results of each study ± standard deviation (SD). If the results showed a skewed distribution, comparisons were performed using the Mann-Whitney *U*. The differences at *p* \< 0.05 (95.5%) were considered significant. Analysis of the obtained results was performed using the computer program XLSTAT.

Results {#S4}
=======

Mean dose of fentanyl used throughout the entire period of anesthetic management for patients of group I constituted 1.09 ±0.03 µg/kg/hour. As to the patients of group II, the total dose of fentanyl during surgery was 21.5 ±3.4 µg/kg, which was 19.7 times significantly higher (*p* = 0.007) than in group I.

Numbers of anastomoses, total duration of operation and anesthesia, as well as duration of CPB and aortic cross-clamping, did not differ significantly between study groups (*p* \> 0.05) ([Table II](#T2){ref-type="table"}).

###### 

Comparison of perioperative results between study groups

  ----------------------------------------------------------------------------------
  Parameter                        Group I\      Group II\     *P*-value,\   
                                   (*n* = 30)    (*n* = 30)    α = 0.05      
  -------------------------------- ------------- ------------- ------------- -------
  Numbers of anastomoses,\                                                   
  *n* (%):                                                                   

                                   2             12 (40.0)     9 (30.0)      0.316

                                   3             18 (60.0)     21 (70.0)     

  Duration of surgery \[min\]      207.4 ±19.2   214.1 ±23.2   0.211         

  Duration of anesthesia \[min\]   228.3 ±25.1   231.4 ±31.2   0.180         

  Duration of CPB \[min\]          82.3 ±11.7    83.9 ±13.3    0.591         

  Duration of aortic\              24.4 ±5.9     25.3 ±5.1     0.570         
  cross-clamping \[min\]                                                     
  ----------------------------------------------------------------------------------

CPB -- cardiopulmonary bypass.

Concerning determination of IL-6 level before the start of CPB, there was no difference in primary values of IL-6 between study groups (*p* = 0.395) ([Table III](#T3){ref-type="table"}).

###### 

Dynamics of changes in IL-6 levels due to CABG with CPB depending on the scheme of anesthetic management

  ----------------------------------------------------------------
  Groups/period          Group I\      Group II\     *P*-value,\
                         (*n* = 30)    (*n* = 30)    α = 0.05
  ---------------------- ------------- ------------- -------------
  Before CPB \[pg/ml\]   6.1 ±1.4      6.4 ±1.3      0.395\^

  After CPB \[pg/ml\]    32.2 ±8.4     44.5 ±16.6    \< 0.0001\^

  *P*-value, α = 0.05    \< 0.0001\*   \< 0.0001\*   
  ----------------------------------------------------------------

CPB -- cardiopulmonary bypass; \^compared between IL-6 value in groups; \*compared between IL-6 value before and after CPB.

The low-dose opioid scheme of anesthetic management was characterized by a significant increase in IL-6 level by 5.26 times (*p* \< 0.0001) compared with primary data ([Table III](#T3){ref-type="table"}). A standard scheme of anesthetic management was also accompanied by significant elevation of IL-6 levels by 6.88 times (*p* \< 0.0001) compared with primary values ([Table III](#T3){ref-type="table"}).

Meanwhile, having compared IL-6 values after cessation of CPB between study groups, it was established that in the patients of group I IL-6 levels were significantly lower by 27.51% (*p* = 0.001) compared with those in patients of group II ([Table III](#T3){ref-type="table"}).

Patients in group I had a significantly shorter time of mechanical ventilation compared to group II (2.1 ±0.7 hours vs. 3.9 ±0.9 hours, *p* = 0.021) ([Table IV](#T4){ref-type="table"}). As to cardiac complications, the frequency of atrial fibrillation (10.0% vs. 30.0%, *p* = 0.052), ventricular tachycardia or fibrillation (3.3% vs. 10.0%, *p* = 0.304), and atrio-ventricular block (13.3% vs. 6.7%, *p* = 0.304) did not differ significantly between study groups. At the same time, low cardiac output syndrome was significantly less frequently reported in patients of group I (10.0% vs. 33.3%, *p* = 0.028). Accordingly, catecholamines were less frequently used in patients in group I on the first postoperative day: norepinephrine (16.7% vs. 43.3%, *p* = 0.025) and dobutamine (30.0% vs. 53.3%, *p* = 0.066). Creatinine and lactate values did not differ on the first postoperative day. In addition, patients in group I spent a significantly shorter time in the ICU (2.5 ±0.7 days vs. 3.5 ±1.0 days, *p* = 0.044), although hospitalization duration did not differ significantly between study groups.

###### 

Post-operative characteristics of study groups

  ---------------------------------------------------------------------------------------------------------
  Variables                                  Group I\                   Group II\     *P*-value,\   
                                             (*n* = 30)                 (*n* = 30)    α = 0.05      
  ------------------------------------------ -------------------------- ------------- ------------- -------
  Postoperative ventilation\                 2.1 ±0.7                   3.9 ±0.9      0.021         
  times \[hours\]                                                                                   

  Reintubation, *n* (%)                      2 (6.7)                    5 (16.7)      0.227         

  Cardiac complication, *n* (%):                                                                    

                                             Atrial fibrillation        3 (10.0)      9 (30.0)      0.052

                                             Ventricular tachycardia\   1 (3.3)       3 (10.0)      0.304
                                             or fibrillation                                        

                                             Atrio-ventricular block    4 (13.3)      2 (6.7)       0.389

                                             Low cardiac output\        3 (10.0)      10 (33.3)     0.028
                                             syndrome                                               

  Catheholamine on first p/o day, *n* (%):                                                          

                                             Norepinephrine             9 (30.0)      16 (53.3)     0.066

                                             Dobutamine                 5 (16.7)      13 (43.3)     0.025

  Lactate \[mmol/l\]:                                                                               

                                             At admission to ICU        2.05 ±0.45    2.28 ±0.56    0.083

  On first postoperative day                 1.87 ±0.27                 1.98 ±0.35    0.337         

  Creatinine \[mmol/l\]:                                                                            

                                             At admission to ICU        102.0 ±18.1   100.5 ±10.7   0.608

  On first postoperative day                 90.5 ±11.4                 91.4 ±10.8    0.743         

  ICU stay \[day\]                           2.5 ±0.7                   3.5 ±1.0      0.044         

  Hospital stay \[day\]                      10.8 ±1.4                  11.6 ±1.8     0.654         

  Hospital mortality, n (%)                  0 (0.0)                    1 (3.3)       0.879         
  ---------------------------------------------------------------------------------------------------------

ICU -- intensive care unit.

Discussion {#S5}
==========

According to study results, the application of multimodal low-opioid anesthesia was associated with significantly lower IL-6 at the end of surgery, shorter mechanical ventilation duration, less frequent low cardiac output syndrome and a need for catecholamines, and shorter ICU stays.

Recently, Rong *et al*. in an extensive meta-analysis, which involved 1400 patients, found that low-dose opioid anesthesia is safe and effective for use in adult patients for cardiosurgical interventions. Moreover, its efficacy does not depend on clinical characteristics of patients, type of opioid used and dose of opioids in groups with low-dose opioid anesthesia \[[@ref12]\].

We chose the determination of IL-6 level to assess the efficacy of a low-dose opioid scheme of anesthetic management, since its concentration in blood serum is a good indicator of the inflammation cascade activation and a predictor of further morbidity and mortality \[[@ref9]\].

Thus, in our research, low-dose anesthesia management was characterized by a significant decrease in inflammatory response, namely, production of pro-inflammatory IL-6, which could be achieved by both direct reduction of fentanyl dose and addition of such medicines as lidocaine, ketamine or dexmedetomidine. Particularly, in the Luggya *et al*. study, administration of sub-narcotic doses of ketamine (0.5 mg/kg) in cardiosurgical interventions was characterized by a significantly lower level of IL-6 in blood serum in the early post-operative period compared with a placebo group \[[@ref13]\].

As for dexmedetomidine, based on the Li *et al*. meta-analysis the use of that agent during general anesthesia significantly decreased the levels of IL-6, IL-8 and tumor necrosis factor α (TNF-α), whereas there was an increase in anti-inflammatory cytokines, such as IL-10 \[[@ref14]\].

A similar effect on dynamics of interleukins was also reported for lidocaine. In particular, according to the de Oliveira *et al*. study, administration of lidocaine at the dose of 2 mg/kg/hour was characterized by a significant decrease in post-operative stress response, including a lower level of IL-6 as compared with placebo groups \[[@ref15]\].

As reported by Yang *et al*. the increased production of IL-6 is associated with decreased myocardial contractility, which may be clinically manifested in low cardiac output syndrome in the postoperative period \[[@ref16]\]. Indeed, in our study, when using low-opioid multimodal anesthesia, both the levels of IL-6 and the incidence of low cardiac output syndrome were significantly lower compared to the standard anesthesia scheme. Accordingly, patients with a standard anesthesia scheme needed more catecholamine use on the first postoperative day.

In addition, atrial fibrillation and ventricular tachycardia or fibrillation were less frequent in patients with multimodal low-opioid anesthesia, although without a significant difference between the groups. First of all, it may be due to the antiarrhythmic properties of lidocaine, which blocks the sodium channels in the conduction system, as well as the muscle cells of the heart, and raises the depolarization threshold, making the heart less likely to initiate or conduct early action potentials \[[@ref17]\]. On the other hand, this effect may also be due to the antiarrhythmic effect of dexmedetomidine -- a highly selective α2 receptor agonist. By activating G-protein transmembrane α2 receptors in the brain, dexmedetomidine can theoretically affect the transmission of sympathetic activity from the central to the peripheral nervous system and elicit an antiarrhythmic effect \[[@ref18]\]. Activation of the vagus nerve was also thought to be a mechanism responsible for the anti-arrhythmic effect of dexmedetomidine \[[@ref19]\].

At the same time, AV block when using dexmedetomidine may also be more common due to activation of the vagus nerve. Thus, in our study, when using a multimodal anesthesia scheme, the AV block was observed more often, although with no significant difference between groups.

As reported by Duncan *et al*. in a recent meta-analysis, the use of dexmedetomidine provided good hemodynamic stability during surgery with less tachycardia and arterial hypertension, a positive effect on confusion and atrial fibrillation, with a shorter time to extubation and a shorter ICU length of stay \[[@ref20]\].

In our study, patients with a low-opioid anesthesia scheme had a shorter duration of mechanical ventilation and stay in the ICU, which was consistent with the work of Guinot's *et al*., who used lidocaine, dexamethasone, and ketamine for the low-opioid anesthesia scheme \[[@ref21]\].

As to ketamine, the main purpose of its use in the scheme of multimodal low-opioid anesthesia is potentiation of analgesics, which reduces the need for opioids \[[@ref22]\].

Our study had several limitations. The relatively small number of patients in our population might limit our study's external validity. In addition, for the analysis of the inflammatory response, we evaluated only one indicator, IL-6, not the cytokine pro- and anti-inflammatory profile as a whole, which may not reflect all aspects of the inflammatory response.

Conclusions {#S6}
===========

Our study demonstrated that the multimodal low-opioid anesthesia with a combination of ketamine, lidocaine, and dexmedetomidine is characterized by relative safety, a lower inflammatory response, lower rates of cardiac complications and shorter duration of mechanical ventilation and stay in ICU. Further randomized studies with more patients are required to confirm these results.
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